Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows

Novo Nordisk (NVO) received accelerated FDA approval for Wegovy to treat liver fibrosis, providing a significant catalyst for the stock currently trading near 52-week lows. This approval offers a strategic growth lever for the company, particularly amid slowing GLP-1 adoption and a recently lowered 2025 sales growth forecast. Coupled with strong bullish technical indicators, the regulatory win positions NVO for a potential rebound and renewed investor interest, signaling expansion into the liver disease treatment market.

Analysis

Novo Nordisk (NVO) has secured a significant catalyst with the FDA's accelerated approval for its drug Wegovy to treat moderate to advanced liver fibrosis. This regulatory win is particularly timely, as the company's stock is trading near 52-week lows and arrives amidst concerns over slowing sales growth for its GLP-1 treatments and rising competition from compounded alternatives. While the company recently lowered its 2025 sales growth forecast to a range of 8-14% from a previous 13-21%, this new indication for Wegovy offers a strategic growth lever that could help stabilize investor sentiment. The technical picture supports a bullish outlook, with NVO trading above its five, 20, and 50-day exponential moving averages, indicating strong buying pressure. However, while the Relative Strength Index (RSI) at 44.88 suggests room for further price appreciation before the stock becomes overbought, the negative MACD reading of -4.00 warrants some caution, signaling a potential need for further confirmation of the nascent uptrend.

Key Decisions for Investors

• Investors could consider the combination of a major FDA approval and a stock price near 52-week lows as a potential strategic entry point, capitalizing on a new growth narrative for Wegovy in liver disease.
• Technical traders should recognize the strong bullish signals from key moving averages but must also monitor the negative MACD for confirmation that the positive price momentum is sustainable.
• It is crucial to weigh this positive regulatory news against the company's recently lowered 2025 sales growth guidance of 8-14%, assessing whether this new indication can materially offset the previously projected slowdown in its core GLP-1 franchise.